Anti-TNF

This is an official prescribing-label update for an adalimumab biosimilar used to treat Crohn’s disease and ulcerative colitis, including pediatric indications and dosing. Changes to indications or pediatric dosing and...

This paper systematically catalogs drugs that have been reported with new or worsening IBD in two large pharmacovigilance databases. Knowing which medications generate strong reporting signals can help clinicians and...

Subcutaneous infliximab could offer children with IBD a more convenient dosing route with higher, steadier drug levels while maintaining remission. Insurance and labeling barriers affected access in this US cohort.

For patients and clinicians facing steroid- and infliximab-refractory acute severe ulcerative colitis, upadacitinib may be a third-line medical option that can produce rapid symptom and CRP improvement and allow some...

The editorial outlines treatment strategies that could affect whether a person with ASUC avoids colectomy, highlights the importance of getting adequate infliximab exposure, and summarizes emerging drug classes that may...

An updated drug label for AMJEVITA affects people with Crohn's disease, ulcerative colitis, and other immune conditions because it defines FDA‑approved uses, dosing schedules (including pediatric dosing), and safety...

Proactive TDM of infliximab was associated with high 1‑ and 2‑year durability in this pediatric Crohn's cohort, and the study flags clinical factors that may predict need to switch biologics. This could be relevant when...

Subcutaneous infliximab may let children on infliximab avoid regular IV infusions while keeping drug levels high and maintaining remission. Results are relevant to families and clinicians considering switching pediatric...

Many patients and clinicians are interested in subcutaneous infliximab because it can be more convenient than IV infusions and may change drug exposure.

The report suggests adding acupuncture to anti-TNF therapy may improve short-term symptom control and mucosal healing and reduce early colectomy risk for a TCM-defined subgroup of ulcerative colitis patients, which could...

Extrapulmonary TB can be triggered or revealed during immunosuppressive biologic therapy and may mimic other causes of liver injury; early recognition and TB-specific testing are important for timely treatment and to...

People with ulcerative colitis who have had colectomy can rarely develop inflammation of the small intestine and high-output stomas that are hard to control.

People with IBD who also have bleeding disorders face special risks during endoscopy, surgery, and when using immunosuppressive drugs. This case shows that coordinated care and hemostatic support can allow diagnosis and...

If validated, a blood biomarker (LRG) could help predict which people with Crohn’s disease are more likely to achieve remission and which biologic might be sustained over a year, informing treatment planning and...

This FDA label update adds or confirms ABRILADA (an adalimumab product) as an approved TNF-blocker option for Crohn’s disease (including children ≥6) and ulcerative colitis (adults). It emphasizes infection and...

The label confirms adalimumab is approved for Crohn’s disease and ulcerative colitis and includes boxed safety warnings—information that directly affects patients considering or taking this TNF‑blocking biologic.

Children with Crohn’s disease have fewer FDA‑approved advanced treatment options than adults, so clinicians and families often must choose among off‑label therapies with limited pediatric evidence.

This is an FDA label entry for YUFLYMA (an adalimumab product) that confirms Crohn’s disease and ulcerative colitis are listed indications and reiterates serious-infection and malignancy warnings for TNF blockers....

The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...

Mucosal healing is an important treatment goal linked to better long-term outcomes, and current anti-TNF therapies achieve mucosal healing in a minority of patients. If adding CDED improves healing, it could offer a...

The study pinpoints a genetic cause (BIRC3 variants) that disrupts a TNF/RIPK1 immune pathway linked to Crohn’s disease, suggesting a targetable mechanism. That could help doctors match patients to treatments and guide...

Scientists found BIRC3 gene changes that cause Crohn’s in some patients and showed those changes drive inflammation through the RIPK1/TNF pathway. That suggests a new, druggable pathway and may help predict who benefits...

This study identifies a specific genetic cause (BIRC3 variants) that drives inflammation through the RIPK1/TNF pathway and points to an existing drug target (RIPK1). If validated, the finding could help match patients to...

This study reports real-world effectiveness of risankizumab for refractory Crohn's disease, showing many patients achieved steroid-free remission. The results are relevant for people weighing treatment options after...

This study suggests risankizumab may improve quality of life and reduce common symptoms (fatigue, mood, urgency) more than ustekinumab for patients with moderate-to-severe Crohn’s disease who didn’t respond to anti-TNF...

There are many new drugs and trials underway for Crohn’s disease, which could expand future treatment options. Recent phase 2 and phase 3 starts from major pharma show active investment in IBD research.

This reports phase 2b trial results showing a fixed-dose combination of two biologics (anti‑TNF + anti‑IL‑23) improved outcomes in people with refractory IBD compared with one biologic alone.

Early “top-down” infliximab plus an immunomodulator was linked to much lower 5-year risk of abdominal surgery, disease progression, and hospitalization versus a step-up approach. This could influence treatment planning...

This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.

Mucosal healing is a treatment goal that aims to stop internal intestinal inflammation, not just symptoms. Achieving mucosal healing is linked with fewer hospitalizations, less need for surgery, and lower rates of...

This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...

Patent expirations can allow biosimilars or generics to enter the U.S. market, which may lower costs and change which versions of IBD biologic drugs are available. Patients on affected medicines should be aware because...

Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.

This study suggests LVV can occur in people with IBD at younger ages and with distinct vascular findings, and it may arise even when gut disease is in remission. That matters for awareness, diagnosis, and coordination...

Patients considering switching biologics or clinicians choosing a second‑line therapy may care because the study suggests ustekinumab had better long‑term persistence and improving remission rates compared with anti‑TNF...

You can have active intestinal inflammation even without clear symptoms; early monitoring and tailored treatment aim to prevent complications and preserve quality of life.

This roundup highlights many drugs and trials in development for Crohn’s disease, including late‑stage studies of biologics and newer oral agents — information that could affect future treatment options. Patients on...

This report outlines which drugs and companies are shaping Crohn’s disease treatment options and predicts market shifts that may affect treatment availability, costs, and future therapy choices.

Cure8 found this source from onlinelibrary.wiley.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Adalimumab, and Anti-TNF. Open the original article for the full details.

A new ustekinumab biosimilar (SELARSDI) is now available in the U.S. for Crohn’s disease and ulcerative colitis, which may expand treatment options and affect access or cost for patients on biologic therapy.

This study suggests a common genetic marker (HLA‑DQA1*05) may help explain why some children stop responding to anti‑TNF drugs and could eventually guide who might benefit from adding methotrexate or closer monitoring.

The article summarizes recent drug approvals and Phase 3 trial results that could affect which biologic treatments are available and how the Crohn's disease treatment market may change. It also gives epidemiology and...

This article reports positive trial results for ustekinumab, a drug that targets IL-12 and IL-23, showing benefit in people with Crohn's disease who did not respond to anti‑TNF drugs. That could expand options for...

This gives adults with moderately to severely active Crohn’s disease another FDA‑approved biologic option, including for people who did not respond to or could not tolerate other therapies.

A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...

The study suggests starting anti-TNF drugs early in children with Crohn's could strongly lower the chance of developing anal fistulas, a serious complication that often requires surgery. Preventing fistulas can reduce...

Fatigue is common in people with Crohn’s disease and ulcerative colitis and can persist even when standard measures say the disease is in remission. This study suggests stricter definitions of remission don’t necessarily...

Perianal fistula complications are serious and difficult to treat. This study suggests starting anti-TNFα therapy early in pediatric Crohn disease may substantially lower the risk of developing these complications,...